• 1
    Venturini AP. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemother 1983; 29: 13.
  • 2
    Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 516.
  • 3
    Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a nonabsorbable rifamycin. J Int Med Res 1988; 16: 31216.
  • 4
    Di Febo G, Calabrese C, Matassoni F. New trends in nonabsorbable antibiotics in gastrointestinal disease. Ital J Gastroenterol 1992; 24: 1013.
  • 5
    Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 5766.
  • 6
    Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res 1984; 36: 929.
  • 7
    Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 25762.
  • 8
    Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984; 3: 3657.
  • 9
    Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16: 11118.
  • 10
    Eftimiadi C, De Leo C, Schito GC. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984; 10: 6916.
  • 11
    Garrod LP, Lambert HP, O'Grady F, Waterworth PM. Antibiotics and chemotherapy. New York : Churchill Livingstone, 1989: 21737.
  • 12
    Enarson DA, Grosset J, Mwinga A, et al. The challenge of tuberculosis: statements on global control and prevention. Lancet 1995; 346: 80919.
  • 13
    Inderlied CB, Salfinger M. Antimicrobial agents and susceptibility tests: mycobacteria. In MurrayPR, BaronEJ, PfallerMA, TenoverFC, YolkenRH eds. Manual of clinical microbiology; Washington , DC : American Society of Microbiology, 1995: 1385404.
  • 14
    Siddiqi SH, Hawkins JE, Laszlo A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by radiometric and two conventional methods. J Clin Microbiol 1985; 22: 91923.
  • 15
    National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing. Proposed standard M24-P, Vol. 10 No. 10. Villanova , PA : NCCLS, 1990.
  • 16
    Murray BE, Hodel-Christian SL. Bacterial resistance: theoretical and practical considerations, mutations to antibiotic resistance, characterization of R plasmid, and detection of plasmid-specific genes. In LorianV, ed. Antibiotics in laboratory medicine. Baltimore : Williams and Wilkins, 1991: 55698.